- Home
- EML vs ALDX Comparison
EML vs ALDX Comparison
Compare EML & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- ALDX
- Stock Information
- Founded
- EML 1858
- ALDX 2004
- Country
- EML United States
- ALDX United States
- Employees
- EML N/A
- ALDX N/A
- Industry
- EML Industrial Machinery/Components
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- ALDX Health Care
- Exchange
- EML Nasdaq
- ALDX Nasdaq
- Market Cap
- EML 130.9M
- ALDX 133.7M
- IPO Year
- EML N/A
- ALDX 2014
- Fundamental
- Price
- EML $22.34
- ALDX $2.24
- Analyst Decision
- EML
- ALDX Strong Buy
- Analyst Count
- EML 0
- ALDX 2
- Target Price
- EML N/A
- ALDX $9.50
- AVG Volume (30 Days)
- EML 14.0K
- ALDX 1.5M
- Earning Date
- EML 05-06-2025
- ALDX 05-20-2025
- Dividend Yield
- EML 1.92%
- ALDX N/A
- EPS Growth
- EML N/A
- ALDX N/A
- EPS
- EML N/A
- ALDX N/A
- Revenue
- EML $271,440,503.00
- ALDX N/A
- Revenue This Year
- EML N/A
- ALDX N/A
- Revenue Next Year
- EML N/A
- ALDX N/A
- P/E Ratio
- EML $11.17
- ALDX N/A
- Revenue Growth
- EML 8.15
- ALDX N/A
- 52 Week Low
- EML $19.06
- ALDX $1.14
- 52 Week High
- EML $35.03
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- EML 51.50
- ALDX 36.53
- Support Level
- EML $19.06
- ALDX $1.90
- Resistance Level
- EML $23.61
- ALDX $2.89
- Average True Range (ATR)
- EML 0.82
- ALDX 0.22
- MACD
- EML 0.53
- ALDX 0.09
- Stochastic Oscillator
- EML 72.09
- ALDX 33.46
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.